Biopharmaceuticals Contract Manufacturing Market Analysis / Research Report 2022-2030: Mergers and Acquisitions in the CMO Industry, CMO Trading at Strong EV/EBITDA Multiples, Current Trends –

DUBLIN–(BUSINESS WIRE)–The report “Biopharmaceuticals Contract Manufacturing Market Size, Share, and Trend Analysis by Source, by Service (Upstream, Downstream, Fill/Finish), by Product (Biologicals), by Region and segment forecast, 2022-2030” has been added to from offer.

The global biopharmaceuticals contract manufacturing market size is expected to reach USD 27.3 billion by 2030, growing at a CAGR of 5.2% from 2022 to 2030.

Growth in the biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors driving the partnership between large molecule manufacturers and contract manufacturing organizations (CMOs).

Contractors are committed to expanding their portfolio of services to meet business demands for regulatory standards and new services. The pandemic has, however, also had negative ripple effects, as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.

The dependence of companies on CMOs for the production of biologics and biosimilars is expected to increase over the forecast period due to the changes adopted by CMOs. This translates into increasing investments in enterprise collaborations with CMOs as well as continued efforts to expand the service portfolio.

The biopharmaceutical supply chain has remained robust and largely unaffected worldwide during the coronavirus outbreak. Additionally, biopharmaceutical manufacturers are seeing increased demand related to COVID-19 vaccine and therapeutics.

Thus, the future holds many opportunities for the market. For example, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement to manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocess industry, and contract services industry. The expansion of fill and finish services and the growing robustness of venture capital investments for the life sciences sector are two significant opportunities that are expected to boost the market.

For example, in 2019, Shanghai HaiHe Biopharma Co. Ltd. has raised $146.6 million in venture capital for its broad portfolio of cancer drugs, which it will use with outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Highlights of the Contract Manufacturing of Biopharmaceuticals Market Report

  • Contract manufacturing of mammalian-based biopharmaceuticals captured the largest market share of around 58% in 2021 owing to the high penetration of mammalian expression systems for biologics development.

  • Of all the services offered in this market, process development contributed the largest share of 33% in 2021, due to high capital investments, especially in downstream processes.

  • Contract manufacturing of organic products dominated its peer segment due to higher demand for the production of organic products. However, the biosimilars segment is growing with a lucrative CAGR of 8.3% due to the economic benefits associated with the development of biosimilars.

  • The presence of an effective regulatory framework for the development of biologics in the United States resulted in a significant North American market share of 34.0% in 2021.

  • However, Asia-Pacific is expected to become the fastest growing regional market with a CAGR of 5.8% from 2022 to 2030, owing to developing economies such as India and China incorporating developments for compete.

Market variables, trends and scope

Market Driver Analysis

  • Increase in CMO investments for capacity expansion

  • Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals

  • Notable growth in organic products

  • Robust biopharmaceutical pipeline

  • Time and cost savings offered by contracted services

Analysis of market constraints

  • Limited outsourcing among well-established biopharmaceutical manufacturers

Opportunity analysis

  • Expansion of fill and finish CMOs

  • Emergence of single-use bioprocessing equipment and solutions

  • Financing & investments

Trend analysis

  • Mergers and Acquisitions in the CMO Industry

  • CMO negotiation at strong EV/EBITDA multiples

  • Current trends in the biopharmaceutical industry

Pipeline analysis

  • Breakdown of products & projects in development by clinical phase

  • Main conclusion of the analysis

  • Biosimilar pipeline analysis, as of February 2018

  • Total global expenditure on biopharmaceutical R&D

  • Number of drugs in clinical development, 2015

Price analysis for process development

  • Cell Line/Expression System Pricing

  • Bioreactor cost

  • Advantage of operating and construction costs with single-use bioprocessing equipment

  • Elements and ranges of bioprocess operating costs

  • Bioprocess Price Analysis by Product Type

  • Downstream Bioprocess Price Analysis

  • Cost analyzes for buffer purchases

Customer Relationship Management in Contract Manufacturing

  • CMO selection process

  • CMO operations and quality management

Competitive landscape

  • Boehringer Ingelheim GmbH

  • lonza

  • Inno Biologics Sdn Bhd

  • Rentschler Biotechnology GmbH

  • Jrs Pharma

  • Celonic SA

  • AGC Organic Products

  • Biomeva GmbH

  • Cmc Biologicals

  • Financial performance of AGC

  • Probiogen

  • Fujifilm Diosynth Biotechnologies USA Inc.

  • Toyobo Co.Ltd.

  • Samsung Organics

  • ThermoFisher Scientific, Inc.

  • Binex Co.Ltd.

  • Wuxi Organic Products

  • Abbvie, Inc.

For more information about this report visit

Comments are closed.